A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 31 Aug 2017 Planned number of patients changed from 799 to 798.
- 31 Aug 2017 Planned End Date changed from 18 Oct 2018 to 24 Dec 2018.
- 31 Aug 2017 Planned primary completion date changed from 17 Sep 2018 to 17 Nov 2018.